The dcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models

Rocky G. Gogliotti, Herminio Cardona, Singh Jasbir, Sophie Bail, Carina Emery, Nancy Kuntz, Michael Jorgensen, M. Durens Madel, Bing Xia, Courtenay Barlow, Christopher R. Heier, Heather L. Plasterer, Vincent Jacques, Megerditch Kiledjian, Jill Jarecki, James Rusche, Christine J. Didonato*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Abstract

Spinal muscular atrophy (SMA) is caused by insufficient levels of the survival motor neuron (SMN) protein due to thefunctional lossof theSMN1geneandtheinabilityof itsparalog,SMN2, tofullycompensateduetoreducedexon 7 splicing efficiency. SinceSMA patients have at least one copy ofSMN2, drug discovery campaigns have sought to identifySMN2inducers.C5-substituted quinazolines increaseSMN2promoter activity in cell-based assays and a derivative, RG3039, has progressed to clinical testing. It is orally bioavailable, brain-penetrant and has been shown to be an inhibitor of the mRNA decapping enzyme, DcpS. Our pharmacological characterization of RG3039, reported here, demonstrates that RG3039 can extend survival and improve function in two SMA mouse models of varyingdiseaseseverity (Taiwanese 5058Hemiand2B/2SMAmice), andpositively impact sneuromuscular pathologies. In 2B/2 SMA mice, RG3039 provided a >600% survival benefit (median 18 days to >112 days) when dosingbegan atP4, highlightingthe importanceof early intervention.We determinedthe minimumeffective dose and the associated pharmacokinetic (PK) and exposure relationship ofRG3039 and DcpS inhibition ex vivo. These data support the long PKhalf-life with extended pharmacodynamic outcome of RG3039 in 2B/2 SMA mice. Inmotorneurons,RG 3039 significantly increased both theaverage number of cell swithgemsandaveragenumber of gems per cell, which is used as an indirectmeasure of SMN levels. These studies contribute to dose selection and exposure estimates for the first studies with RG3039 in human subjects.

Original languageEnglish (US)
Article numberddt258
Pages (from-to)4084-4101
Number of pages18
JournalHuman molecular genetics
Volume22
Issue number20
DOIs
StatePublished - Oct 2013

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'The dcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models'. Together they form a unique fingerprint.

Cite this